Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation

PRIMARY OBJECTIVES:

I. To determine whether early response of the research positron emission tomography
(PET)-computed tomography(CT) scan measured by change in Standard Uptake Value (SUV)max
relative to baseline scan can predict induction chemoradiation therapy (CRT) failures sooner
than post-treatment PET-CT scan.

II. To determine the optimal timing for 18FDG PET-CT that best predicts for induction CRT
failure.

SECONDARY OBJECTIVES:

I. To correlate early 18 fludeoxyglucose (FDG) PET-CT response metrics with pathologic
response, progression-free survival separately for: induction CRT failures vs. non-failures,
or overall survival separately for induction CRT failures vs. non-failures.

OUTLINE: Patients are randomized to 1 of 3 groups.

Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28
fractions with concurrent chemotherapy.

GROUP A: Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of
chemotherapy).

GROUP B: Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of
chemotherapy).

GROUP C: Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of
chemotherapy).

Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and
undergo standard tumor resection.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months thereafter.